Salute e Benessere
Caristo Congratulates Abcentra for First Patient Dosed Successfully in Phase 2b 'FORTIFY' Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease
The clinical trial ( ; NCT06927739) is a multi-center, randomized, placebo-controlled, double-blind trial designed to evaluate the efficacy of orticumab in reducing local coronary inflammation in patients with a history of type 1 myocardial infarction (MI) and elevated coronary inflammation. A total of 240 adults with a history of type 1 MI and elevated Fat Attenuation Index (FAI) Score — determined using Caristo's technology — are being enrolled at 40 sites in the U.S. and Europe .
Caristo's core laboratory responsibilities for the trial include:
"We chose Caristo because their cutting-edge imaging technology allows us to measure coronary inflammation with unprecedented precision," said . "This will be vital to confirming orticumab's potential to address coronary inflammation, one of the root causes of heart attacks."
"Pharma and biotech sponsors are increasingly turning to Caristo to help select trial candidates and evaluate how both coronary plaque and inflammation — two critical and independent predictors of heart attack risk — are affected by a trial drug," said . "We are proud to partner with Abcentra on and to support their groundbreaking work in developing targeted anti-inflammatory therapies with chosen as the primary outcome endpoint."
Caristo Diagnostics is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford , Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo.com.
Abcentra is a clinical stage biopharmaceutical company pioneering targeted therapies for cardiovascular inflammation. The company's first-in-class monoclonal antibody, orticumab, targets oxidized LDL to quell persistent inflammation within atherosclerotic plaques, offering a novel approach for patients at risk of recurrent cardiovascular events. For more information, visit abcentra.com.
Logo: https://mma.prnewswire.com/media/2054669/5509761/Caristo_Logo.jpg
Logo: https://mma.prnewswire.com/media/2380898/4635069/Abcentra_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/caristo-congratulates-abcentra-for-first-patient-dosed-successfully-in-phase-2b-fortify-clinical-trial-evaluating-orticumab-in-patients-with-cardiovascular-disease-302556837.html